Exhibit 99.1

 

	News Release

 

Media Contacts:	Steve Cragle	Investor Contacts:	Joe Romanelli
	(908) 423-3461		(908) 423-5185
	Lainie Keller		Carol Ferguson
	(908) 423-4187		(908) 423-4465

 

Merck Announces First-Quarter 2014 Financial Results

 

·      First-Quarter 2014 Non-GAAP EPS of $0.88, Excluding Certain Items; GAAP EPS of $0.57; Confirms 2014 Full-Year Non-GAAP EPS Target of $3.35 to $3.53, Excluding Certain Items; GAAP EPS Range of $2.15 to $2.47

 

·      Worldwide Sales were $10.3 Billion, a Decrease of 4 Percent, Reflecting Unfavorable Impact of Patent Expiries and a 2 Percent Unfavorable Impact from Foreign Exchange

 

·      Strategic Initiatives Drove Cost Reductions and Portfolio Divestitures, Generating First-Quarter 2014 Benefits

 

·      Sales of REMICADE, SIMPONI and ISENTRESS, as well as Diabetes and Vaccines Franchises Grew

 

·      FDA Approved GRASTEK and RAGWITEK Sublingual Allergen Extract Immunotherapy Tablets and Accepted Filings for V503 and Suvorexant; Company Announced Progress in Key Clinical Programs Including HCV and HIV

 

·      Repurchased $7.5 Billion of Common Stock Over Previous 12 Months as Part of Ongoing Share Repurchase Program

 

WHITEHOUSE STATION, N.J., April 29, 2014 — Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced financial results for the first quarter of 2014.

 

$ in millions, except EPS amounts		First Quarter 2014		First Quarter 2013
Sales		$10,264		$10,671
GAAP EPS		0.57		0.52
Non-GAAP EPS that excludes items listed below1		0.88		0.85
GAAP Net Income2		1,705		1,593
Non-GAAP Net Income that excludes items listed below1,2		2,601		2,585

 

1  Merck is providing certain 2014 and 2013 non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance. This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP. For description of the items, see Table 2a, including the related footnotes, attached to this release.

2  Net income attributable to Merck & Co., Inc.

 

 

Non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the first quarter of $0.88 exclude acquisition-related costs, restructuring costs and certain other items.

 

A reconciliation of GAAP to non-GAAP net income and EPS is provided in the tables that follow.

 

$ in millions, except EPS amounts		First Quarter 2014		First Quarter 2013
EPS
GAAP EPS		$0.57		$0.52
Difference3		0.31		0.33
Non-GAAP EPS that excludes items listed below1		$0.88		$0.85
Net Income
GAAP net income2		$1,705		$1,593
Difference		896		992
Non-GAAP net income that excludes items listed below1,2		$2,601		$2,585
Decrease (Increase) in Net Income Due to Excluded Items:
Acquisition-related costs4		$1,137		$1,237
Restructuring costs		326		194
Net decrease (increase) in income before taxes		1,463		1,431
Income tax (benefit) expense5		(567	)	(439	)
Decrease (increase) in net income		$896		$992

 

“Investing in the best opportunities for growth while being disciplined in managing our costs enabled us to deliver bottom-line performance,” said Kenneth C. Frazier, chairman and chief executive officer, Merck. “This is an exciting time as we prepare to commercialize the next wave of innovation coming out of Merck’s research labs over the next few years.”

 

Select Revenue Highlights

 

Worldwide sales were $10.3 billion for the first quarter of 2014, a decrease of 4 percent compared with the first quarter of 2013, including a 2 percent negative effect from foreign exchange.

 

3  Represents the difference between calculated GAAP EPS and calculated non-GAAP EPS, which may be different than the amount calculated by dividing the impact of the excluded items by the weighted-average shares for the period.

4  Includes expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions, as well as intangible asset impairment charges. Also includes integration and other costs associated with mergers and acquisitions.

5  Includes the estimated tax impact on the reconciling items. Amount for 2014 also includes a benefit of approximately $300 million associated with a capital loss generated in the quarter. In addition, amount for 2013 includes a benefit of approximately $160 million associated with the resolution of a previously disclosed federal income tax issue.

 

Page 2

 

The following table reflects sales of the company’s top pharmaceutical products, as well as total sales of animal health and consumer care products.

 

$ in millions		First Quarter 2014		First Quarter 2013		Change		Change Ex-exchange
Total Sales		$10,264		$10,671		-4	%	-2	%
Pharmaceutical		8,451		8,891		-5	%	-3	%
JANUVIA/JANUMET		1,334		1,293		3	%	5	%
ZETIA/VYTORIN		972		1,023		-5	%	-4	%
REMICADE		604		549		10	%	7	%
ISENTRESS		390		362		8	%	8	%
GARDASIL		383		390		-2	%	2	%
NASONEX		312		385		-19	%	-16	%
PROQUAD, M-M-R II and VARIVAX		280		272		3	%	4	%
SINGULAIR		271		337		-20	%	-13	%
Animal Health		813		840		-3	%	0	%
Consumer Care		546		571		-4	%	-3	%
Other Revenues		454		369		23	%	17	%

 

Pharmaceutical Revenue Performance

 

First-quarter pharmaceutical sales declined 5 percent to $8.5 billion, including a 2 percent negative impact due to foreign exchange. Expected declines occurred in several products due to the ongoing impact of the loss of market exclusivity, including TEMODAR (temozolomide), SINGULAIR (montelukast sodium), NASONEX (mometasone furoate monohydrate) and COZAAR (losartan potassium)/HYZAAR (losartan potassium and hydrochlorothiazide). These declines were partially offset by growth in the diabetes franchise of JANUVIA (sitagliptin)/JANUMET (sitagliptin and metformin HCI), as well as REMICADE (infliximab), SIMPONI (golimumab) and ISENTRESS (raltegravir).

 

Worldwide combined sales of JANUVIA and JANUMET, medicines that help lower blood sugar levels in adults with type 2 diabetes, grew 3 percent to $1.3 billion in the first quarter, including a 2 percent negative impact from foreign exchange. The growth reflects higher sales in Europe, the United States and the emerging markets, which were partially offset by declines in Japan.

 

Combined sales of ZETIA (ezetimibe) and VYTORIN (ezetimibe/simvastatin), medicines for lowering LDL cholesterol, decreased 5 percent to $972 million in the first quarter, including a 1 percent negative impact from foreign exchange. The decrease was driven by lower demand in the United States.

 

Combined sales of REMICADE and SIMPONI, treatments for inflammatory diseases, grew 16 percent to $760 million in the first quarter, including a 3 percent positive impact from

 

Page 3

 

foreign exchange. The growth reflects continued European launches of SIMPONI and continued growth in several markets in Europe.

 

Worldwide sales of ISENTRESS, an HIV integrase inhibitor for use in combination with other antiretroviral agents for the treatment of HIV-1 infection, increased 8 percent to $390 million in the first quarter. The increase was driven by strong growth in Europe and the emerging markets.

 

Merck’s sales of GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant], a vaccine to help prevent certain diseases caused by four types of human papillomavirus (HPV), were $383 million, a decrease of 2 percent for the first quarter, including a 4 percent negative impact from foreign exchange. The results reflect lower sales in Japan following the government’s decision in July 2013 to suspend active promotion of HPV vaccines, partially offset by higher sales in the United States and from the national immunization program in Brazil.

 

Worldwide sales of SINGULAIR, a once-a-day oral medicine for the chronic treatment of asthma and the relief of symptoms of allergic rhinitis, declined 20 percent to $271 million in the first quarter, mostly due to patent expiries in major European markets in February 2013.

 

Animal Health Revenue Performance

 

Animal Health sales totaled $813 million for the first quarter of 2014, a 3 percent decrease compared with the first quarter of 2013, including a 3 percent negative impact due to foreign exchange. The results reflect the company’s decision last year to voluntarily suspend sales of ZILMAX (zilpaterol hydrochloride), a feed supplement for beef cattle, in the United States and Canada. Excluding sales of ZILMAX, Animal Health sales increased 5 percent in the first quarter, driven by higher sales of poultry, swine and aqua products. In the first quarter, the European Commission granted marketing authorization for BRAVECTO (fluralaner), a chewable tablet that kills fleas and ticks in dogs for up to 12 weeks; the company anticipates approval in the United States later in 2014.

 

Consumer Care Revenue Performance

 

First-quarter global sales of Consumer Care products were $546 million, a decrease of 4 percent compared to the first quarter of 2013, including a 1 percent negative impact due to foreign exchange. The sales decrease was primarily due to product divestitures and a shortened allergy season in North America.

 

Page 4

 

Other Revenue Performance

 

Other revenues — primarily comprising alliance revenue, miscellaneous corporate revenues and third-party manufacturing sales — increased 23 percent to $454 million compared to the first quarter of 2013. The increase was primarily driven by $232 million in proceeds from the sale of marketing rights for SAPHRIS (asenapine) in the United States, partially offset by lower revenue from AstraZeneca (AZ) recorded by Merck, which declined 44 percent to $147 million in the first quarter of 2014, as well as by lower third-party manufacturing sales.

 

The company expects that AZ will elect to exercise its option to buy the company’s interest in a subsidiary and, through it, the company’s interest in Nexium and Prilosec. If AZ exercises its option, as of July 1, 2014, Merck will no longer record equity income from AZ and supply sales to AZ will end.

 

First-Quarter Expense and Other Information

 

The costs detailed below totaled $8.3 billion on a GAAP basis during the first quarter of 2014 and include $1.5 billion of acquisition-related costs and restructuring costs.

 

		Included in expenses for the period
$ in millions		GAAP			Acquisition- Related Costs4			Restructuring Costs			Non-GAAP1
First Quarter 2014
Materials and production		$3,903			$1,126			$119			$2,658
Marketing and administrative		2,734			11			31			2,692
Research and development		1,574			—			51			1,523
Restructuring costs		125			—			125			—
First Quarter 2013
Materials and production		$3,959			$1,184			$43			$2,732
Marketing and administrative		2,987			23			17			2,947
Research and development		1,907			30			15			1,862
Restructuring costs		119			—			119			—

 

The gross margin was 62.0 percent for the first quarter of 2014 compared to 62.9 percent for the first quarter of 2013, reflecting 12.1 and 11.5 percentage point unfavorable impacts, respectively, from the acquisition-related costs and restructuring costs noted above. The non-GAAP gross margin decline primarily reflects the impact of product mix, partially offset by the favorable impact of foreign exchange.

 

Page 5

 

Marketing and administrative expenses, on a non-GAAP basis, were $2.7 billion in the first quarter of 2014, a decrease from $2.9 billion in the same period of 2013. The decline was primarily due to productivity measures.

 

Research and development (R&D) expenses, on a non-GAAP basis, were $1.5 billion in the first quarter of 2014, a decrease from $1.9 billion in the first quarter of 2013. The decline reflects targeted reductions and lower clinical development spending as a result of portfolio prioritization and increased focus on the company’s key therapeutic opportunities, as well as timing of certain programs set to begin throughout the rest of 2014.

 

Equity income from affiliates was $124 million for the first quarter, primarily reflecting the performance of partnerships with AZ and Sanofi Pasteur MSD.

 

Other (income) expense, net, was $39 million of income in the first quarter of 2014, compared to $282 million of expense in the first quarter of 2013. The first quarter of 2014 includes a $182 million gain on the divestiture of the company’s Sirna Therapeutics, Inc. subsidiary. The first quarter of 2013 included approximately $140 million of exchange losses due to a Venezuelan currency devaluation.

 

The GAAP effective tax rate of 17.2 percent for the first quarter of 2014 reflects the impacts of acquisition-related costs and restructuring costs, as well as a benefit of approximately $300 million associated with a capital loss generated in the quarter. The non-GAAP effective tax rate, which excludes these items, was 26.1 percent for the quarter.

 

Key Developments

 

Clinical

 

·                  Interim Phase 2 data for MK-5172/MK-8742, an investigational oral combination regimen for treatment of chronic hepatitis C virus (HCV), presented at the 2014 Annual Meeting of the European Association for the Study of the Liver, showed sustained viral response in hard-to-cure and treatment-naïve, non-cirrhotic patients.

 

·                  Interim Phase 2b data on doravirine (MK-1439), an investigational treatment for HIV, presented at the 21st Conference on Retroviruses and Opportunistic Infections, demonstrated potent antiretroviral activity in treatment-naïve HIV-1 infected adults in combination with tenofovir/emtricitabine after 24 weeks of therapy; a Phase 3 clinical program is planned to begin in the second half of 2014.

 

Regulatory

 

·                  The U.S. Food and Drug Administration (FDA) approved GRASTEK (Timothy Grass Pollen Allergen Extract) and RAGWITEK (Short Ragweed Pollen Allergen Extract), the company’s sublingual allergen extract immunotherapy tablets.

 

Page 6

 

·                  The FDA accepted a Biologics License Application for V503, a 9-valent HPV vaccine candidate, in February.

 

·                  The FDA accepted the resubmission of a New Drug Application for suvorexant for insomnia in April.

 

·                  The European Committee for Medicinal Products for Human Use issued a positive opinion for vintafolide in patients with platinum-resistant ovarian cancer.

 

Financial Targets

 

Merck reiterated that it expects full-year 2014 non-GAAP EPS to be between $3.35 and $3.53, and 2014 GAAP EPS to be between $2.15 and $2.47. The 2014 non-GAAP range excludes acquisition-related costs, costs related to restructuring programs, potential gains associated with the expected termination of the AZ joint venture and certain other items. The 2014 EPS targets (both non-GAAP and GAAP) include a potential devaluation of the Venezuelan Bolivar.

 

At current exchange rates, Merck continues to expect full-year 2014 revenues to be between $42.4 billion and $43.2 billion. This includes the expectation that AZ will elect to end the partnership between the companies at mid-year, as well as lost revenue from patent expirations across multiple markets and previously announced product divestitures.

 

In addition, the company continues to expect full-year 2014 non-GAAP marketing and administrative as well as R&D expenses to be below 2013 levels. The company continues to anticipate its full-year 2014 non-GAAP tax rate to be in the range of 24 to 26 percent; the rate does not include a 2014 benefit of an R&D tax credit.

 

A reconciliation of anticipated 2014 EPS, as reported in accordance with GAAP to non-GAAP EPS that excludes certain items, is provided in the table below.

 

$ in millions, except EPS amounts		Full Year 2014
GAAP EPS		$2.15 to $2.47
Difference3		1.20 to 1.06
Non-GAAP EPS that excludes items listed below		$3.35 to $3.53
Acquisition-related costs4		$4,600 to $4,350
Restructuring costs		1,300 to 1,000
Gain on AZ option exercise		(700) to (725)
Net decrease (increase) in income before taxes		5,200 to 4,625
Estimated income tax (benefit) expense		(1,675) to (1,535)
Decrease (increase) in net income		$3,525 to $3,090

 

Page 7

 

Total Employees

 

As of March 31, 2014, Merck had approximately 74,000 employees worldwide. In addition, the company’s joint ventures in China and Brazil, which are included in the consolidated results of Merck, had about 1,200 employees.

 

Earnings Conference Call

 

Investors, journalists and the general public may access a live audio webcast of the call today at 8:00 a.m. EDT on Merck’s website at http://www.merck.com/investors/events-and-presentations/home.html. Institutional investors and analysts can participate in the call by dialing (706) 758-9927 or (877) 381-5782 and using ID code number 17424702. Members of the media are invited to monitor the call by dialing (706) 758-9928 or (800) 399-7917 and using ID code number 17424702. Journalists who wish to ask questions are requested to contact a member of Merck’s Media Relations team at the conclusion of the call.

 

About Merck

 

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube. You can also follow our Twitter conversation at $MRK.

 

Forward-Looking Statement

 

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

 

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the

 

Page 8

 

United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

 

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

 

###

 

Page 9

 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS - GAAP

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 1

 

		GAAP
		1Q14			1Q13			% Change
Sales		$	10,264		$	10,671		-4	%
Costs, Expenses and Other
Materials and production (1)		3,903			3,959			-1	%
Marketing and administrative (1)		2,734			2,987			-8	%
Research and development (1)		1,574			1,907			-17	%
Restructuring costs (2)		125			119			5	%
Equity income from affiliates (3)		(124		)	(133		)	-7	%
Other (income) expense, net (1) (4)		(39		)	282			*
Income Before Taxes		2,091			1,550			35	%
Income Tax (Benefit) Provision		360			(66		)
Net Income		1,731			1,616			7	%
Less: Net Income Attributable to Noncontrolling Interests		26			23
Net Income Attributable to Merck & Co., Inc.		$	1,705		$	1,593		7	%
Earnings per Common Share Assuming Dilution		$	0.57		$	0.52		10	%
Average Shares Outstanding Assuming Dilution		2,971			3,053
Tax Rate (5)		17.2		%	-4.3		%

 

* 100% or greater

 

(1) Amounts include the impact of acquisition-related costs, restructuring costs and certain other items. See accompanying tables for details.

 

(2) Represents separation and other related costs associated with restructuring activities under the company’s formal restructuring programs.

 

(3) Primarily reflects equity income from the AstraZeneca LP and Sanofi Pasteur MSD partnerships.

 

(4) Other (income) expense, net in the first quarter of 2014 includes a gain of $182 million on the divestiture of the company’s Sirna Therapeutics, Inc. subsidiary. Other (income) expense, net in the first quarter of 2013 reflects approximately $140 million of losses due to exchange as a result of a Venezuelan currency devaluation.

 

(5) The GAAP effective tax rate for the first quarter of 2014 reflects a benefit of approximately $300 million associated with a capital loss generated in the quarter. The GAAP effective tax rate for the first quarter of 2013 reflects the favorable impact of various discrete items, including the impact of tax legislation enacted in the first quarter of 2013, a reduction in tax reserves upon expiration of applicable statute of limitations, as well as a benefit of approximately $160 million associated with the resolution of a previously disclosed federal income tax issue.

 

 

MERCK & CO., INC.

CONSOLIDATED STATEMENT OF OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

FIRST QUARTER 2014

(AMOUNTS IN MILLIONS, EXCEPT PER SHARE FIGURES)

(UNAUDITED)

Table 2a

 

					Acquisition-		Restructuring		Adjustment
		GAAP			Related Costs (1)		Costs (2)		Subtotal			Non-GAAP
Sales		$	10,264									$	10,264
Costs, Expenses and Other
Materials and production		3,903			1,126		119		1,245			2,658
Marketing and administrative		2,734			11		31		42			2,692
Research and development		1,574					51		51			1,523
Restructuring costs		125					125		125			—
Equity income from affiliates		(124		)					—			(124		)
Other (income) expense, net		(39		)					—			(39		)
Income Before Taxes		2,091			(1,137	)	(326	)	(1,463		)	3,554
Taxes on Income		360							(567		)(3)	927
Net Income		1,731							(896		)	2,627
Less: Net Income Attributable to Noncontrolling Interests		26							—			26
Net Income Attributable to Merck & Co., Inc.		$	1,705						$	(896	)	$	2,601
Earnings per Common Share Assuming Dilution		$	0.57									$	0.88
Average Shares Outstanding Assuming Dilution		2,971										2,971
Tax Rate		17.2		%								26.1		%

 

Merck is providing non-GAAP information that excludes certain items because of the nature of these items and the impact they have on the analysis of underlying business performance and trends. Management believes that providing this information enhances investors’ understanding of the company’s performance.  This information should be considered in addition to, but not in lieu of, information prepared in accordance with GAAP.

 

(1) Amounts included in materials and production costs reflect expenses for the amortization of intangible assets recognized as a result of mergers and acquisitions.  Amounts included in marketing and administrative expenses reflect merger integration costs.

 

(2) Amounts primarily include employee separation costs and accelerated depreciation associated with facilities to be closed or divested related to actions under the company’s formal restructuring programs.

 

(3) Represents the estimated tax impact on the reconciling items, as well as a benefit of approximately $300 million associated with a capital loss generated in the quarter.

 

 

MERCK & CO., INC.

FRANCHISE / KEY PRODUCT SALES

(AMOUNTS IN MILLIONS)

Table 3

 

		2014			2013															% Change
		1Q			1Q			2Q			3Q			4Q			Full Year			1Q
TOTAL SALES (1)		$	10,264		$	10,671		$	11,010		$	11,032		$	11,319		$	44,033		-4
PHARMACEUTICAL		8,451			8,891			9,310			9,475			9,760			37,437			-5
Primary Care and Women’s Health
Cardiovascular
Zetia		611			629			650			662			716			2,658			-3
Vytorin		361			394			417			396			436			1,643			-8
Diabetes
Januvia		858			884			1,072			927			1,121			4,004			-3
Janumet		476			409			474			442			503			1,829			16
General Medicine & Women’s Health
NuvaRing		168			151			171			170			193			686			11
Follistim AQ		110			122			134			124			101			481			-10
Dulera		102			68			79			82			95			324			49
Implanon		102			84			102			96			120			403			21
Hospital and Specialty
Hepatitis
Peglntron		112			126			142			104			124			496			-11
Victrelis		59			110			116			121			81			428			-46
HIV
Isentress		390			362			412			427			442			1,643			8
Hospital
Cancidas		166			162			163			151			183			660			3
Invanz		114			110			120			130			128			488			4
Noxafil		74			65			71			75			98			309			13
Bridion		73			63			69			75			82			288			16
Primaxin		71			84			85			88			79			335			-15
Immunology
Remicade		604			549			527			574			620			2,271			10
Simponi		157			108			120			126			146			500			45
Other
Cosopt / Trusopt		99			105			103			104			103			416			-7
Oncology
Emend		122			116			135			123			134			507			5
Temodar		83			216			219			162			111			708			-62
Diversified Brands
Respiratory
Nasonex		312			385			325			297			327			1,335			-19
Singulair		271			337			281			280			298			1,196			-20
Clarinex		62			61			64			54			55			235			2
Other
Cozaar / Hyzaar		205			267			255			238			246			1,006			-23
Arcoxia		128			121			121			112			131			484			6
Fosamax		123			137			144			140			139			560			-10
Propecia		74			68			67			71			77			283			8
Zocor		64			82			74			65			79			301			-21
Remeron		50			52			53			44			56			206			-4
Vaccines
Gardasil		383			390			383			665			394			1,831			-2
ProQuad, M-M-R II and Varivax		280			272			339			421			273			1,306			3
RotaTeq		169			162			144			201			129			636			4
Zostavax		142			168			141			185			264			758			-15
Pneumovax 23		101			111			108			193			241			653			-9
Other Pharmaceutical (2)		1,175			1,361			1,430			1,350			1,435			5,570			-14
ANIMAL HEALTH		813			840			851			800			871			3,362			-3
CONSUMER CARE (3)		546			571			490			443			390			1,894			-4
Claritin OTC		170			177			78			123			92			471			-4
Other Revenues (4)		454			369			359			314			298			1,340			23
Astra		147			262			245			220			193			920			-44

 

Sum of quarterly amounts may not equal year-to-date amounts due to rounding.

(1) Only select products are shown.

(2) Includes Pharmaceutical products not individually shown above. Other Vaccines sales included in Other Pharmaceutical were $98 million in the first quarter of 2014. Other Vaccines sales included in Other Pharmaceutical were $53 million, $86 million, $127 million, and $101 million for the first, second, third, and fourth quarters of 2013, respectively.

(3) The decrease in Consumer Care sales in the second quarter and full year of 2013 resulted from the ongoing termination in China of distribution arrangements and a reversal of sales previously made to those distributors, together with associated termination costs.

(4) Other revenues are comprised primarily of alliance revenue, third-party manufacturing sales and miscellaneous corporate revenues, including revenue hedging activities. On October 1, 2013, the company divested a substantial portion of its third-party manufacturing sales. In addition, Other revenues in the fourth quarter and full year of 2013 reflect $50 million of revenue for the out-license of a pipeline compound. Other revenues in the first quarter 2014 include $232 million of revenue recognized in connection with the sale of U.S. Saphris rights.